Ablexis, LLC

In June 2018, Ablexis LLC, and Deerfield Management announced the acquisition of Ablexis by Deerfield. This acquisition creates a long-term partnership that will enable Ablexis to expand industry access to its AlivaMab® Mouse technology, the Company’s next-generation transgenic mouse platform for human antibody drug discovery.


ReMed, founded in 1984, is a leading operator of rehabilitation facilities that provides short and long-term outpatient and community-based services for people with Acquired Brain Injury (ABI). With approximately 3.4 million ABI cases reported per year, the industry lacks treatment options that allow for independent living.

Adeptus Health

In October 2017 after its emergence from bankruptcy, Deerfield completed the acquisition of reorganized Adeptus Health. Adeptus is an operator of fully equipped, freestanding emergency rooms that provide coordinated care to patients 24/7. Its site model has the capability to address crucial acuity care needs while also providing reduced wait times for patients.

Press releases

Adeptus Health and Deerfield Join Forces to Enable High Quality Emergency Care
April 2017

Deerfield Management Completes Acquisition of Adeptus Health
October 2017


DepoMed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. In a transformative transaction, the company agreed to acquire the U.S. rights to NUCYNTA, a drug for severe pain, from Janssen Pharmaceuticals for $1.05 billion.

To finance the purchase, Deerfield and Pharmakon structured a flexible 7 year debt facility. The total facility was $575 million of which Deerfield provided $375 million.

Horizon Pharma

Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed and is commercializing products to primary care, orthopedic surgeons and rheumatologists. The Company markets DUEXIS®, RAYOS®/LODOTRA® and VIMOVO®, which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. On March 19th, Horizon announced the acquisition of Vidara Therapeutics International Ltd.

FSC Laboratories

FSC Laboratories is a specialty pharmaceutical and medical device company dedicated to pediatric primary care and select subspecialties. The company was founded in 2003 and has grown its business through product acquisitions, in-licensing, and co-promotion agreements. In 2008, FSC expanded its operating infrastructure and launched a commercialization effort.


Following several failed attempts by original management to commercialize BiDil® for the treatment of heart failure in black patients, Deerfield purchased 100% of the equity of NitroMed in April of 2009. During the initial year, we relocated the headquarters and improved profitability of the base business by reducing costs. While lack of promotion through the remainder of 2009 led to a gentle decline in sales, the improved profitability substantially de-risked the purchase and validated the return proposition.